Changing trends in phase 1 oncology clinical trials
- Journal Title
- Contemporary Clinical Trials Communications
- Publication Type
- Research article
- Abstract
- The Ph1 oncology trial landscape is evolving in response to advances in understanding of cancer biology, novel drug discovery platforms, and therapeutic modalities. To uncover emerging trends in oncology drug development, we identified 7,061 solid tumour Ph1 trials (2009-2021) from clinicaltrials.gov to determine the numbers of trials commenced, therapeutic classes, combinations, tumour streams, and geographical distribution. Ph1 oncology trials increased by an average of 5.2 %/year. There was a significant relative increase in the number of immunotherapy studies and a significant relative decrease in trials containing chemotherapy. Between 2009 and 2021, multi-agent combination trials outnumbered single-agent trials and single-class trials outnumbered multimodal combination trials. The proportion conducted in the Asia-Pacific significantly increased. Multiregional trials decreased during the COVID-19 pandemic, reducing projected trial numbers in Asia-Pacific and Europe whilst increasing single-region trials in North America. Further study is required to track recovery post-pandemic, and the emergence of novel modalities (e.g. ADCs and cellular therapies).
- Publisher
- Elsevier
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.conctc.2023.101239
- Open Access at Publisher's Site
https://doi.org/10.1016/j.conctc.2023.101239- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-02-13 06:41:44
Last Modified: 2024-02-13 06:51:51